Clinical Trial: Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07311746) titled 'Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia' on Dec. 29, 2025.

Brief Summary: The goal of this clinical research study is to learn if the combination of ruxolitinib with cladribine and venetoclax can help to control the disease in patients with R/R T-PLL.

Study Start Date: June 01, 2026

Study Type: INTERVENTIONAL

Condition: T-cell Prolymphocytic Leukemia Refractory T-Cell Prolymphocytic Leukemia

Intervention: DRUG: Ruxolitinib

Given orally

DRUG: Cladribine

Given by injection

DRUG: Venetoclax

Taken by mouth

Recruitment Status: NOT_YET_RECRUITING...